Last updated: February 24, 2026
What is NDC 68462-0297?
NDC 68462-0297 is a drug marketed as Abaloparatide (Tymlos), developed by Radius Health. It is an anabolic agent used for treating osteoporosis in postmenopausal women at high risk of fracture, including those with previous fractures or glucocorticoid-induced osteoporosis.
Market Size and Demand Drivers
Osteoporosis Market Overview
- The global osteoporosis drugs market was valued at approximately USD 8.2 billion in 2022.
- Projected CAGR (Compound Annual Growth Rate): 3.8% from 2023-2030 [1].
- Key segments: anabolic agents (like Abaloparatide and Teriparatide) and antiresorptive agents.
Relevant Patient Population
- Estimated 200 million women worldwide suffer from osteoporosis [2].
- Postmenopausal women constitute 85-90% of osteoporosis cases.
- High-risk populations include patients with prior fractures, glucocorticoid use, or severe osteoporosis.
Competition and Market Share
- Primary competitors: Teriparatide (Forteo) by Lilly, Romosozumab (Evenity) by Amgen.
- Estimated market share distribution (2023): Forteo holds approx. 60%, Abaloparatide holds around 15-20%, others account for the remaining share [3].
Regulatory Status and Market Access
- Approved by FDA in 2017 for postmenopausal women at high fracture risk.
- Received EMA approval in 2018.
- Reimbursement policies subject to regional health authorities; high-cost drugs often face access challenges.
Price Trends and Projections
Current Pricing
- List Price: U.S. wholesale acquisition cost (WAC) for Tymlos is approximately USD 4,200 per 28-day supply (one month’s treatment).
- Actual patient cost varies with insurance and subsidies, but list price remains the benchmark.
- Treatment duration typically spans 18-24 months, leading to a total treatment cost of USD 75,600–USD 100,800 per patient.
Price Trends (2017–2023)
- Initial launch price: around USD 4,200 per month.
- Slight discounts and rebates emerging in 2020 due to increased competition and payer negotiations.
- No significant downward price trend yet, but future reductions possible if biosimilars or competing products gain approval.
Future Price Projections (2024–2028)
| Year |
Estimated List Price per Month |
Justification |
| 2024 |
USD 4,000 – USD 4,200 |
Static pricing with minor discounts; market saturation |
| 2025 |
USD 3,800 – USD 4,000 |
Payer pressure and increased competition |
| 2026 |
USD 3,600 – USD 3,800 |
Entry of biosimilars or generics if approved |
| 2027 |
USD 3,400 – USD 3,600 |
Payer-driven discounts; cost containment strategies |
| 2028 |
USD 3,200 – USD 3,400 |
Further biosimilar development and adoption |
Impact of Biosimilars and Market Dynamics
- Biosimilar development could reduce prices by 25-40% upon approval.
- The timeline for biosimilar entry remains uncertain, with regulatory approval processes typically spanning 18–36 months post-launch.
Market Penetration and Adoption
- Adoption rate expected to accelerate as more real-world evidence supports efficacy and safety.
- Payer coverage expansion will influence market penetration.
- Cost-effectiveness models suggest willingness to pay increases if long-term fracture reduction is demonstrated.
Risks and Opportunities
Risks:
- Competition from Romosozumab (sclerostin inhibitor), which has a different mechanism and potentially larger market share.
- Patent litigation or delays in biosimilar approvals.
- Reimbursement restrictions or formularies limiting access.
Opportunities:
- Expansion into markets outside the U.S., particularly in Europe and Asia.
- Orphan drug status in select regions may provide pricing advantages.
- Potential for combination therapies in osteoporosis management.
Key Takeaways
- Abaloparatide (NDC 68462-0297) remains priced around USD 4,200/month in the U.S.
- Total treatment costs range up to USD 100,000 per patient.
- Market share is consolidating around dominant anabolic agents with moderate growth potential.
- Price reductions may occur driven by biosimilar entry and payer pressure, with projections indicating a downward trend over 2024-2028.
- Competition and regulatory changes present both risks and opportunities for future market dynamics.
FAQs
Q1: How does Abaloparatide's price compare to similar osteoporosis drugs?
A1: It is similar in price to Teriparatide, which ranges from USD 4,000–USD 4,500 per month. Romosozumab, a newer agent, costs approximately USD 2,600 per month, potentially influencing competitive dynamics.
Q2: What factors could accelerate price reductions for Abaloparatide?
A2: Approval of biosimilars, stricter payer negotiations, and expanded market access could lead to faster price declines.
Q3: How does the treatment duration for Abaloparatide impact overall costs?
A3: Typical treatment spans 18–24 months, resulting in significant cumulative costs that influence cost-effectiveness assessments and reimbursement decisions.
Q4: Are there regional variations in the drug's pricing?
A4: Yes; prices differ across countries depending on regulations, market competition, and reimbursement policies, often leading to lower prices outside the U.S.
Q5: What is the outlook for Abaloparatide’s market share in the coming years?
A5: It is expected to stabilize around 15-20%, with growth contingent on new indications, market expansion, and competitive pressures.
References
- MarketsandMarkets. (2022). Osteoporosis Drugs Market Report.
- International Osteoporosis Foundation. (2021). Global Population Data.
- IQVIA. (2023). Market Share Data for Osteoporosis Treatments.
[1] MarketsandMarkets. (2022). Osteoporosis Drugs Market Report.
